Odevixibat FDA Approval Status
FDA Approved: No
Generic name: odevixibat
Company: Albireo Pharma, Inc.
Treatment for: Progressive Familial Intrahepatic Cholestasis (PFIC)
Odevixibat is a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) in development for the treatment of rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome.
Development Timeline for odevixibat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
